Pharmaceutical compositions for antibodies and making and using the same
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- INVETX INC
- Filing Date
- 2026-05-12
- Publication Date
- 2026-07-17
AI Technical Summary
Existing pharmaceutical formulations for antibodies are unstable in solution and lack stability over extended periods, limiting their suitability for various administration routes.
A stable pharmaceutical formulation comprising an antibody with a canine CH2, CH3, IgG Fc region variant or its FcRn binding region, combined with a buffer at pH 4.5 to 7.0, osmotic pressure regulator, stabilizer, and surfactant, ensuring stability for up to twenty-four months and suitability for oral, rectal, mucosal, enteral, or parenteral administration.
The formulation provides enhanced stability and suitability for multiple administration routes, maintaining efficacy over an extended period.
Smart Images
Figure 00000124_0000 
Figure 00000125_0000 
Figure 00000125_0001
Abstract
Description
IRN: 538632 Title: Antibody Pharmaceutical Composition and Its Preparation and Use Abstract: This disclosure provides a stable pharmaceutical formulation comprising: an antibody having a canine CH2, CH3, IgG Fc region variant or a canine FcRn binding region thereof; a buffer with a pH in the range of 4.5 to 7.0; an osmotic pressure regulator and / or stabilizer; a chelating agent; and a surfactant; wherein the formulation is stable in solution for up to twenty-four months and is suitable for oral, rectal, mucosal, enteral, or parenteral administration.
Claims
What is claimed is:
1. A stable pharmaceutical formulation comprising:(a) 5 to 100 mg / ml of an antibody comprising a polypeptide having a canine or feline CDR of variable antibody domain, CH2, CH3, IgG Fc region variant, or a canine or feline FcRn-binding region thereof;;(b) 4.0 to 50 mM of a buffering agent at a pH in the range of from 4.5 to 7. 0;(c) 0.01 to 35% (w / v) of a tonicity and / or a stabilizing agent; and(d) 0.01 to 10 % (w / v) of a surfactant; wherein the formulation is a single-dose or multi-dose formulation, and wherein the formulation retains stability for up to twenty-four months in solution.
2. The pharmaceutical formulation of claim 1 further comprising 0.01 to 5.0 mM of a chelating agent.
3. The pharmaceutical formulation of claim 1, wherein the multi-dose formulation further comprises an antimicrobial preservative selected from a group comprising benzyl alcohol, phenol, m-cresol, benzalkonium chloride, benzalthonium chloride, phenoxyethanol and methyl paraben or mixtures thereof at about a concentration of 0.1 to 1.5% (w.v).
4. The pharmaceutical formulation of claim 1, wherein the buffering agent is selected from a group consisting of sodium acetate, histidine, histidine hydrochloride (HC1), succinate, phosphate, Tris, diethanolamine, citrate, acetate, other organic acids and mixtures thereof.
5. The pharmaceutical formulation of claim 1, wherein the buffering agent is present at a concentration of 5 to 30 mM and maintains a physiologically suitable pH in the range of from pH 5 to pH 6.5.
6. The pharmaceutical formulation of claim 1, wherein the tonicity and / or stabilizing agent is selected from a group consisting of CaCh, NaCl, MgCh, lactose, sorbitol, sucrose, mannitol, trehalose, raffinose, polyethylene glycol, hydroxyethyl starch, glycine and mixtures thereof.
7. The pharmaceutical formulation of claim 6, wherein the tonicity and / or stabilizing agent is preferably sucrose, trehalose, sorbitol.
8. The pharmaceutical formulation of claim 1, wherein the tonicity and / or stabilizing and / or stabilizing agent is present at a concentration of 0.02% to 10% (w.v).
9. The pharmaceutical formulation of claim 1, wherein the chelating agent is selected from a group consisting of aminopolycarboxylic acids, hydroxyaminocarboxylic acids, N- substituted glycines, 2-(2-amino-2-oxoethyl) aminoethane sulfonic acid (BES), deferoxamine (DEF), citric acid, niacinamide, desoxycholates, diethylenetriamine pentaacetic acid 5 (DTP A), nitrilotriacetic acid (NTA), N-2-acetamido-2-iminodiacetic acid (ADA), bis(aminoethyl)glycolether, N,N,N',N'-tetraacetic acid (EGTA), transdiaminocyclohexane tetraacetic acid (DCTA), glutamic acid, and aspartic acid, N- hydroxy ethyliminodiacetic acid (HIMDA), N,N-bis-hydroxy ethylglycine (bicine) and N- (trishydroxymethylmethyl) 10 glycine (tri cine), glycylglycine, sodium desoxy cholate, ethylenediamine, propylenediamine, diethylenetriamine, triethylenetetraamine (trien), ethylenediaminetetraacetic acid (EDTA), disodium EDTA, calcium EDTA oxalic acid, malate, citric acid, citric acid monohydrate, and trisodium citrate-dihydrate, 8- hydroxyquinolate, amino acids, histidine, cysteine, methionine, peptides, polypeptides, and proteins and mixtures thereof.
10. The pharmaceutical formulation of claim 9, wherein the chelating agent is preferably EDTA, disodium EDTA, calcium EDTA.
11. The pharmaceutical formulation of claim 9, wherein the chelating agent is present at a concentration of 0.01 to 5 mM.
12. The pharmaceutical formulation of claim 1, wherein the surfactant is selected from a group consisting of polysorbates, poloxamers, tritons, sodium dodecyl sulfate, sodium laurel sulfate, sodium octyl glycoside, lauryl-sulfobetaine, myristyl-sulfobetaine, linoleyl-sulfobetaine, stearyl-sulfobetaine, lauryl-sarcosine, myristyl -sarcosine, linoleyl- sarcosine, stearyl-sarcosine, linoleyl-betaine, myristyl-betaine, cetyl-betaine, lauroamidopropyl-betaine, cocamidopropyl-betaine, linoleamidopropyl-betaine,myristamidopropyl-betaine, palmidopropyl-betaine, isostearamidopropyl-betaine, myristamidopropyl-dimethylamine, palmidopropyl-dimethylamine, isostearamidopropyl- dimethylamine, sodium methyl cocoyl-taurate, disodium methyl oleyl -taurate, dihydroxypropyl PEG 5 linoleammonium chloride, polyethylene glycol, polypropylene glycol, and mixtures thereof.
13. The pharmaceutical formulation of claim 12, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 21, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85, and mixtures thereof.
14. The pharmaceutical formulation of claim 1, wherein the surfactant is present at a concentration of 0.002 to 0. 5% (w / v).
15. The pharmaceutical formulation of claim 1, further comprising an antioxidant selected from a group consisting of GLA (gamma-linolenic acid)-lipoic acid, DHA (docosahexaenoic acid)-lipoic acid, GLA-tocopherol, di-GLA-3, 3 '-thiodipropionic acid, DGLA (dihomo-gamma-linolenic acid), AA (arachidonic acid), SA (salicylic acid), EPA (eicosapentaenoic acid) or DHA (docosahexaenoic acid), phenolic anti-oxidants including, polyenes, unsaturated sterols, ascorbic acid, organosulfur compounds, terpenes and amino acid antioxidants.
16. The pharmaceutical formulation of claim 15, wherein the amino acid antioxidants are selected from a group consisting of methionine, cysteine, carnosine and analogs thereof.
17. The pharmaceutical formulation of claim 15, wherein the antioxidant is present at a concentration of 0.01 mM to about 50 mM.
18. The pharmaceutical formulation of claim 1, further comprising a preservative present at a concentration of 0.001 % w / v to 10% w / v wherein the preservative is selected from a group consisting of phenols, m-cresol, benzyl alcohol, benzalkonium chloride, benzalthonium chloride, phenoxyethanol and methyl paraben.
19. The pharmaceutical formulation of claim 1, wherein the formulation is suitable for oral, rectal, transmucosal, intestinal, or parenteral administration.
20. The pharmaceutical formulation of claim 19, wherein parenteral administration is selected from intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intra-ossial, intradermal or subcutaneous administration.